Glycopyrronium bromide oral solution for the treatment of severe sialorrhoea in children and adolescents aged 3 years and older

NHS Devon

Commissioning policy

The routine commissioning of glycopyrronium bromide oral solution for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders is accepted in Devon. The Formulary Interface Group should include this in locally defined treatment recommendations. Prescribers should note that due to bioavailability differences brands of glycopyrronium bromide oral solution are not directly interchangeable.

Rationale for the decision

Glycopyrronium bromide is a competitive antagonist of muscarinic receptors in the autonomic nervous system and is licensed for the symptomatic treatment of severe chronic pathological drooling, or sialorrhoea, in children and adolescents aged 3 years and older with chronic neurological disorders.

Evidence from clinical trials demonstrates that glycopyrronium bromide is more efficacious than placebo, and failed to find a significant difference in efficacy compared to transdermal hyoscine for this indication.

It offers an additional option for the treatment of severe sialorrhoea in children and adolescents with chronic neurological disorders.

Guidance notes on exceptionality

Where the circumstances of treatment for an individual patient do not meet the criteria described above exceptional funding can be sought. Individual cases will be reviewed by the appropriate panel of the ICB upon receipt of a completed application from the patient's GP, consultant or clinician. Applications cannot be considered from patients personally.

Date of publication:	Version:
10.10.2019	Policy agreed by NHS Devon CCG Policy adopted by NHS Devon ICB on 01.07.2022